Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 800

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 1A
Chunk 800
---
will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent
information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and
may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate,
we may have insufficient recourse against third parties for misappropriating the trade secret.

Third-party claims of intellectual property
infringement may prevent or delay our development and commercialization efforts.

Our commercial success depends
in part on our avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings
involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including with respect to
NO delivery systems and formulations, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings
before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which
are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical
industries expand and more patents are issued, the risk increases that our approved product or product candidates may be subject to claims
of infringement of the patent rights of third parties.

Third parties may assert that
we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims
to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our approved product
or product candidates. We do not know whether there are any third-party patents that would impair our ability to commercialize our approved
product or such product candidates. We also cannot be sure that we have identified each and every patent and pending patent application
in the U.S. and abroad that is relevant or necessary to the commercialization of our approved product and product candidates. Because
patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents
that our approved product or product candidates may infringe. In addition, third parties may obtain patents in the future and claim that
use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover
the manufacturing process of our approved product or any of our product candidates, any molecules formed during the manufacturing process
or any final product itself, the holders of any such patents may be able to block our ability to